Clinical trials show average weight loss of 15-20% of body weight over 68 weeks with semaglutide (Wegovy) and 15-22% with tirzepatide (Zepbound)
The impact of endometriosis on dietary choices and activities of everyday life: a cross-sectional study
Reaching end stage kidney disease, an individualized life plan for kidney care should be discussed with patients and in the absence of technique-associated contraindications, many of these will choose peritoneal dialysis (PD) as a form of kidney replacement therapy (KRT)
Schrder W, Sommer H, Gladstone BP, et al
Inflammation and Cardiovascular Benefits Triple agonists are being studied for additional benefits including: reduced inflammation lower triglycerides improved cholesterol markers reduced cardiovascular risk factors Stronger Metabolic Shift The deeper the metabolic improvement, the more sustainable the long-term weight management
Consult your doctor before starting any weight loss program